# A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases

> **NCT07333118** · EARLY_PHASE1 · RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 22 (estimated)

## Conditions studied

- Moderate to Severe Refractory Autoimmune Disease

## Interventions

- **BIOLOGICAL:** GT801 Injection

## Key facts

- **NCT ID:** NCT07333118
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07333118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07333118, "A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07333118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*